Query: stroke

Filtered By:
Source: American Heart Journal

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 410 results found since Jan 2013.

Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Conclusions GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy–based strategy in subjects without need of chronic oral anticoagulation.
Source: American Heart Journal - November 26, 2016 Category: Cardiology Source Type: research

Atorvastatin for high-risk statin-na ïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial
Conclusion In contrast to the prior observational and trial data, the LOAD trial has neutral results and did not demonstrate a reduction in major cardiovascular complications after a short-term perioperative course of statin in statin-naïve patients undergoing noncardiac surgery. We demonstrated, however, that a large multicenter blinded perioperative statin trial for high-risk statin-naïve patients is feasible and should be done to definitely establish the efficacy and safety of statin in this patient population.
Source: American Heart Journal - November 26, 2016 Category: Cardiology Source Type: research

Cardiorespiratory fitness and nonfatalcardiovascular events: A population-based follow-up study
Conclusion In this Finnish population, there is a strong, inverse, and independent association between CRF and acute nonfatal MI and HF risk.
Source: American Heart Journal - November 22, 2016 Category: Cardiology Source Type: research

β-blocker dosage and outcomes after acute coronary syndrome
Conclusions In ACS patients, rates of MACE for high-dose and low-dose β-blocker doses are similar. These findings question the importance of achieving a high dose of β-blocker in ACS patients and highlight the need for further investigation of this clinical question.
Source: American Heart Journal - November 18, 2016 Category: Cardiology Source Type: research

Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)
Conclusion The PRAGUE-17 trial will determine if LAA occlusion is noninferior to treatment with NOAC in moderate- to high-risk AF patients.
Source: American Heart Journal - November 16, 2016 Category: Cardiology Source Type: research

Atorvastatin for High Risk Statin-Na ïve Patients Undergoing Noncardiac Surgery: The LOAD Randomized Trial
Conclusion In contrast to the prior observational and trial data, the LOAD trial has neutral results and did not demonstrate a reduction in major cardiovascular complications after a short-term perioperative course of statin in statin-naïve patients undergoing non-cardiac surgery. We demonstrated, however, that a large multicenter blinded perioperative statin trial for high risk statin-naïve patients is feasible, and should be done to definitely establish the efficacy and safety of statin in this patient population. Clinical trial registration: Clinicaltrials.gov Identifier: NCT01543555
Source: American Heart Journal - November 10, 2016 Category: Cardiology Source Type: research

Cardiorespiratory Fitness and Non-fatal Cardiovascular events: A Population based Follow-up Study
Conclusion In this Finnish population, there is a strong, inverse, and independent association between CRF and acute non-fatal MI and HF risk.
Source: American Heart Journal - November 3, 2016 Category: Cardiology Source Type: research

Trial design: Rivaroxaban for the prevention of major cardiovascular events post transcatheter aortic valve replacement: rationale and design of the GALILEO study
Conclusions GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy-based strategy in subjects without need of chronic oral anticoagulation.
Source: American Heart Journal - November 1, 2016 Category: Cardiology Source Type: research

Beta-blocker Dosage and Outcomes After Acute Coronary Syndrome
Conclusions In ACS patients, rates of MACE for high-dose and low-dose beta-blocker doses are similar. These findings question the importance of achieving a high-dose of beta-blocker in ACS patients and highlight the need of further investigation of this clinical question.
Source: American Heart Journal - October 24, 2016 Category: Cardiology Source Type: research

Interventional left atrial appendage closure vs. novel anticoagulation agents in atrial fibrillation patients indicated for long term anti-coagulation (PRAGUE-17 study)
Conclusion The PRAGUE-17 trial will determine if LAA occlusion is non-inferior to treatment with NOAC in moderate to high-risk AF patients.
Source: American Heart Journal - October 12, 2016 Category: Cardiology Source Type: research

Prevalence and Outcome of Thrombotic and Embolic Complications in Adults after Fontan Operation
Conclusions TEC was not uncommon; risk factors for TEC were APC and atrial arrhythmias. Most patients were treated successfully with warfarin alone. A second TEC occurred in most patients whose anticoagulation was discontinued because of bleeding events.
Source: American Heart Journal - October 5, 2016 Category: Cardiology Source Type: research

On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
Conclusions This analysis provides additional support for the efficacy and safety of adding Ez to S in this high-risk, post-ACS population.
Source: American Heart Journal - September 23, 2016 Category: Cardiology Source Type: research

Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke
Conclusions Physicians were more likely to prescribe high-intensity statins in statin-naïve patients as compared with intensifying existing statin therapy, and their prescription pattern was lower after CVA vs ACS.
Source: American Heart Journal - September 18, 2016 Category: Cardiology Source Type: research

Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System
Conclusions Among US veterans with new AF and additional risk factors for stroke, only about half receive OAC, and the proportion is declining.
Source: American Heart Journal - September 4, 2016 Category: Cardiology Source Type: research

Influence of access site choice for cardiac catheterization on risk of adverse neurological events: A systematic review and meta-analysis
Conclusions Radial access site utilization for cardiac catheterization is not associated with an increased risk of stroke events. This data provides reassurance and should remove another potential barrier to conversion to a ‘default’ radial practice among those who are currently predominantly femoral operators.
Source: American Heart Journal - August 29, 2016 Category: Cardiology Source Type: research

Impact of the 2013 ACC/AHA cholesterol guidelines on the prescription of high intensity statins in patients hospitalized for acute coronary syndrome or stroke
Conclusions Physicians were more likely to prescribe high-intensity statins in statin naïve patients as compared to intensifying existing statin therapy; and their prescription pattern was lower following CVA versus ACS.
Source: American Heart Journal - August 27, 2016 Category: Cardiology Source Type: research

A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: design and rationale of the randomized Elderly-ACS 2 Study
Conclusion The Elderly-ACS 2 study is a multicenter, randomized trial comparing a strategy of dual antiplatelet therapy with a reduced dose of prasugrel with a standard dose of clopidogrel in elderly patients with ACS undergoing percutaneous revascularization. (The Elderly ACS 2 trial: NCT01777503)
Source: American Heart Journal - August 27, 2016 Category: Cardiology Source Type: research

Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial
Publication date: Available online 26 August 2016 Source:American Heart Journal Author(s): Ernest Spitzer, Nicolas M. Van Mieghem, Philippe Pibarot, Rebecca T. Hahn, Susheel Kodali, Mathew S. Maurer, Tamim M. Nazif, Josep Rodés-Cabau, Jean-Michel Paradis, Arie-Pieter Kappetein, Ori Ben-Yehuda, Gerrit-Anne van Es, Faouzi Kallel, William N. Anderson, Jan Tijssen, Martin B. Leon Background Co-existence of moderate aortic stenosis (AS) in patients with heart failure with reduced ejection fraction (HFrEF) is not uncommon. Moderate AS increases afterload, while pharmacological reduction of afterload is a pillar of contemporary...
Source: American Heart Journal - August 27, 2016 Category: Cardiology Source Type: research

Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis; a nationwide population-based study
Conclusions In a nationwide cohort study with MHV and high TTR, heart failure and atrial fibrillation did not appear as risk factors of stroke/TE.
Source: American Heart Journal - August 12, 2016 Category: Cardiology Source Type: research

Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) – DEVOTE 1
Publication date: September 2016 Source:American Heart Journal, Volume 179 Author(s): Steven P. Marso, Darren K. McGuire, Bernard Zinman, Neil R. Poulter, Scott S. Emerson, Thomas R. Pieber, Richard E. Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown Frandsen, Rasmus Rabøl, John B. Buse DEVOTE was designed to evaluate the cardiovascular safety of insulin degludec (IDeg) vs insulin glargine U100 (IGlar) in patients with T2D at high risk of cardiovascular events. DEVOTE is a phase 3b, multicenter, international, randomized, double-blind, active comparator-controlled trial, designed as an event-driven t...
Source: American Heart Journal - July 31, 2016 Category: Cardiology Source Type: research

Rationale and design of a randomized trial of automated hovering for post –myocardial infarction patients: The HeartStrong program
Conclusions Our randomized controlled trial of the HeartStrong program will provide an evaluation of a state-of-the-art behavioral economic intervention with a number of important pragmatic features. These include a tailored intervention responding to patient activity, streamlining of consent and implementation processes using new technologies, outcomes centrally important to patients, and the ability to implement rapid-cycle innovation.
Source: American Heart Journal - July 28, 2016 Category: Cardiology Source Type: research

A comparison of the CHARGE –AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study
Conclusion The CHARGE-AF risk score performed better than the CHA2DS2-VASc risk score at predicting AF in a community-based cohort.
Source: American Heart Journal - July 21, 2016 Category: Cardiology Source Type: research

Effect of age on efficacy and safety of vorapaxar in patients with non –ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial
Conclusion Older patients had a greater risk for ischemic and bleeding events; however, the efficacy and safety of vorapaxar in NSTE ACS were not significantly influenced by age.
Source: American Heart Journal - July 21, 2016 Category: Cardiology Source Type: research

Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial
Conclusions Aspirin use at baseline was associated with an increased risk for bleeding and all-cause death in ROCKET AF, a risk most pronounced in patients without known CAD. Although these findings may reflect unmeasured clinical factors, further investigation is warranted to determine optimal aspirin use in patients with AF.
Source: American Heart Journal - July 10, 2016 Category: Cardiology Source Type: research

Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program
Conclusions Our randomized controlled trial of the HeartStrong program will provide an evaluation of a state-of-the-art behavioral economic intervention with a number of important pragmatic features. These include a tailored intervention responding to patient activity, streamlining of consent and implementation processes using new technologies, outcomes centrally important to patients, and the ability to implement rapid-cycle innovation.
Source: American Heart Journal - July 9, 2016 Category: Cardiology Source Type: research

Complete Versus Incomplete Revascularization in Patients with Multivessel Coronary Artery Disease Treated With Drug-Eluting Stents
Conclusions Among patients with multivessel CAD treated with DES, as compared with CR, IR was associated with similar risk of death. However, IR was associated with a higher risk of MI during follow-up.
Source: American Heart Journal - July 8, 2016 Category: Cardiology Source Type: research

Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial
Publication date: September 2016 Source:American Heart Journal, Volume 179 Author(s): Michael D. Ezekowitz, Charles V. Pollack, Paul Sanders, Jonathan L. Halperin, Judith Spahr, Nilo Cater, William Petkun, Andrei Breazna, Paulus Kirchhof, Jonas Oldgren Stroke prevention in anticoagulation-naïve patients with atrial fibrillation undergoing cardioversion has not been systematically studied. Objective To determine outcomes in anticoagulation-naïve patients (defined as those receiving an anticoagulant for <48 hours during the index episode of atrial fibrillation) scheduled for cardioversion. Methods This...
Source: American Heart Journal - July 6, 2016 Category: Cardiology Source Type: research

Cardiovascular safety of insulin degludec versus insulin glargine in patients at high risk of cardiovascular events: Design of the DEVOTE Cardiovascular Outcomes Trial (DEVOTE 1)
Publication date: Available online 18 June 2016 Source:American Heart Journal Author(s): Steven P. Marso, Darren K. McGuire, Bernard Zinman, Neil R. Poulter, Scott S. Emerson, Thomas R. Pieber, Richard E. Pratley, Poul-Martin Haahr, Martin Lange, Kirstine Brown Frandsen, Rasmus Rabøl, John B. Buse The Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was designed to evaluate the cardiovascular safety of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes at high risk of c...
Source: American Heart Journal - June 18, 2016 Category: Cardiology Source Type: research

A Randomized, Parallel Group, Double-Blind Study of Ticagrelor compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation: Rationale and Design of the Ticagrelor in CABG (TiCAB-) Trial
Publication date: Available online 18 June 2016 Source:American Heart Journal Author(s): Antoinette de Waha, Sigrid Sandner, Moritz von Scheidt, Andreas Boening, Katharina Koch-Buettner, Dieter Hammel, Rainer Hambrecht, Bernhard C. Danner, Friedrich A. Schöndube, Gerold Goerlach, Theodor Fischlein, Michael Schmoeckel, Martin Oberhoffer, Rainer Schulz, Thomas Walther, Tibor Ziegelhöffer, Christoph Knosalla, Felix Schönrath, Friedhelm Beyersdorf, Matthias Siepe, Tim Attmann, Martin Misfeld, Friedrich-Wilhelm Mohr, Hans-Hinrich Sievers, Alexander Joost, Leon M. Putman, Günther Laufer, Christia...
Source: American Heart Journal - June 18, 2016 Category: Cardiology Source Type: research

Progressive Intermediate-Term Improvement in Ventricular and Atrioventricular Interaction after Transcatheter Pulmonary Valve Replacement in Patients with Right Ventricular Outflow Tract Obstruction
Conclusions Patients with RVOT obstruction had biventricular systolic and diastolic dysfunction at BL. Relieving RVOT obstruction with TPVR reduced adverse ventricular and compensatory atrioventricular interaction, resulting in progressive biventricular functional improvement and remodeling at early and mid-term FU.
Source: American Heart Journal - June 16, 2016 Category: Cardiology Source Type: research

Effect of Age on Efficacy and Safety of Vorapaxar in Patients with Non–ST-Segment Elevation Acute Coronary Syndrome: Insights from the TRACER Trial
Conclusion Older patients had a greater risk for ischemic and bleeding events; however, the efficacy and safety of vorapaxar in NSTE ACS were not significantly influenced by age.
Source: American Heart Journal - June 9, 2016 Category: Cardiology Source Type: research

A comparison of the CHARGE–AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study
Conclusion The CHARGE-AF risk score performed better than the CHA2DS2-VASc risk score at predicting AF in a community-based cohort.
Source: American Heart Journal - June 1, 2016 Category: Cardiology Source Type: research

Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2
Conclusion The R2CHADS2 score estimates postoperative events with acceptable accuracy and if further validated may be used as a simple preoperative risk tool calculator.
Source: American Heart Journal - May 31, 2016 Category: Cardiology Source Type: research

A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study
Conclusion The CHARGE-AF risk score performed better than the CHA2DS2-VASc risk score at predicting AF in a community-based cohort.
Source: American Heart Journal - May 17, 2016 Category: Cardiology Source Type: research

Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Conclusions In patients with acute coronary syndrome undergoing early PCI, the efficacy and safety of ticagrelor as compared with clopidogrel were not modified by GPI use according to the primary efficacy and safety end point of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs with) GPI treatment.
Source: American Heart Journal - May 8, 2016 Category: Cardiology Source Type: research

Atrial Fibrillation without Comorbidities: Prevalence, Incidence and Prognosis (from the Framingham Heart Study)
Conclusions The risk of cardiovascular outcomes and mortality among individuals with AF without comorbidities is lower than typical AF, but is significantly elevated compared with matched individuals without AF.
Source: American Heart Journal - April 30, 2016 Category: Cardiology Source Type: research

Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial
Publication date: Available online 29 April 2016 Source:American Heart Journal Author(s): C. Camaro, S.A.J. Damen, M.A. Brouwer, E. Kedhi, S.W. Lee, M. Verdoia, L. Barbieri, A. Rognoni, A.W.J. van t Hof, E. Ligtenberg, M.J. de Boer, H. Suryapranata, G. De Luca Background The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients treated with drug eluting stents (DES) is still under debate. Recent meta-analyses on≤6months versus 12months DAPT suggest that bleeding rates can be reduced, without a higher rate of thrombotic complications. In particular, the COMBO dual th...
Source: American Heart Journal - April 30, 2016 Category: Cardiology Source Type: research

Prediction of Postoperative Cardiac Surgery Outcomes With a Novel Score: R2CHADS2
Conclusion The R2CHADS2 score estimates postoperative events with acceptable accuracy and if validated can be used as a simple preoperative drisk tool calculator.
Source: American Heart Journal - April 30, 2016 Category: Cardiology Source Type: research

Rationale and Design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A Multicenter, Cluster-Randomized Trial of P2Y12 Receptor Inhibitor Copayment Reduction after Myocardial Infarction
Conclusion ARTEMIS will be the largest randomized assessment of a medication copayment reduction intervention on medication persistence, clinical outcomes, treatment selection, and cost of care after acute MI.
Source: American Heart Journal - April 19, 2016 Category: Cardiology Source Type: research

Effect of Apixaban on Brain Infarction and Microbleeds: AVERROES-MRI Assessment Study
Conclusions Apixaban treatment was associated with a non-significant trend toward reduction in the composite of clinical ischemic stroke and covert embolic-pattern infarction and did not increase the number of microbleeds in patients with atrial fibrillation, compared with aspirin.
Source: American Heart Journal - April 17, 2016 Category: Cardiology Source Type: research

Impact of Glycoprotein IIb/IIIa Inhibitors on the Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients with Acute Coronary Syndromes - Analysis from the PLATO (Platelet Inhibition and Patient Outcomes) Trial
Conclusions In patients with ACS undergoing early PCI the efficacy and safety of ticagrelor as compared with clopidogrel was not modified by GPI use according to the primary efficacy and safety endpoint of the trial, although there were indications of greater benefit on definite stent thrombosis and more major or minor bleeding with ticagrelor in patients without (vs. with) GPI treatment.
Source: American Heart Journal - April 14, 2016 Category: Cardiology Source Type: research

A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT AF): design and rationale
The objective of this prospective, cluster randomized controlled trial (IMPACT-AF; ClinicalTrials.gov #NCT02082548) is to determine whether a comprehensive customized intervention will increase the rate and persistence of use of OAC in patients with AF. IMPACT-AF will be conducted in approximately 50 centers in 5 low- to middle-income countries. Before randomization, sites within countries will be paired to match in size, practice type and baseline rate of OAC use. Site pairs will be randomized to intervention versus control. In total, 40 to 70 patients with AF and at least 2 CHA2DS2-VASc risk factors will be enrolled at e...
Source: American Heart Journal - March 21, 2016 Category: Cardiology Source Type: research

Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study
This study will provide important information about demographics, practice patterns, treatments, and associated outcomes in patients with AF. The results of this registry will also allow Brazilian data to be put in perspective with other AF registries across the world and provide opportunities to improve care of patients with AF in Brazil.
Source: American Heart Journal - March 9, 2016 Category: Cardiology Source Type: research

A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study
Publication date: April 2016 Source:American Heart Journal, Volume 174 Author(s): Thomas J. Povsic, Matthew T. Roe, Erik Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, Charles Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown to ...
Source: American Heart Journal - February 23, 2016 Category: Cardiology Source Type: research

Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos Results
Conclusions Hispanic/Latino LS7s compared favorably with existing national estimates; however, we found areas for improvement. Several Hispanic/Latino LS7 strengths and weaknesses varied by sex and heritage, providing important information to guide targeted health promotion efforts toward achieving 2020 goals.
Source: American Heart Journal - February 20, 2016 Category: Cardiology Source Type: research

Family History of Atrial Fibrillation is Associated with Earlier-onset and More Symptomatic Atrial Fibrillation: Results From the ORBIT-AF Registry
Conclusions Patients with a family history of AF developed AF at a younger age, had less comorbidity, and were more symptomatic. Once AF developed, no significantly increased risks of AF progression and thromboembolism were associated with a family history of AF compared with no family history.
Source: American Heart Journal - February 20, 2016 Category: Cardiology Source Type: research

Prior Bleeding, Future Bleeding and Stroke Risk with Oral Anticoagulation in Atrial Fibrillation: What New Lessons Can ARISTOTLE Teach Us?
Publication date: Available online 13 February 2016 Source:American Heart Journal Author(s): Shaun G. Goodman
Source: American Heart Journal - February 14, 2016 Category: Cardiology Source Type: research

Individualized approaches to thromboprophylaxis in atrial fibrillation
Publication date: March 2016 Source:American Heart Journal, Volume 173 Author(s): Oliver J. Ziff, A. John Camm Atrial fibrillation (AF) is the most common arrhythmia worldwide. The prevalence of AF in persons older than 55 years is at least 33.5 million globally and is predicted to more than double in the next half-century. Anticoagulation, heart rate control, and heart rhythm control comprise the 3 main treatment strategies in AF. Anticoagulation is aimed at preventing debilitating stroke, systemic embolism, and associated mortality. Historically, anticoagulation in AF was achieved with a vitamin K antagonist such as ...
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research

Design and Rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) Trial
Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
Publication date: Available online 28 January 2016 Source:American Heart Journal Author(s): C. Reith, L. Blackwell, J. Emberson, B. Mihaylova, J. Armitage, J. Fulcher, A. Keech, J. Simes, C. Baigent, R. Collins The Cholesterol Treatment Trialists’ (CTT) Collaboration was originally established to conduct individual patient data meta-analyses of major vascular events, cause-specific mortality and site-specific cancers in large, long-term, randomized trials of statin therapy (and other cholesterol-modifying treatments). The results of the trials of statin therapy, and their associated meta-analyses, have shown ...
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research